61 related articles for article (PubMed ID: 29046866)
1. Systematic Functional Annotation of Somatic Mutations in Cancer.
Ng PK; Li J; Jeong KJ; Shao S; Chen H; Tsang YH; Sengupta S; Wang Z; Bhavana VH; Tran R; Soewito S; Minussi DC; Moreno D; Kong K; Dogruluk T; Lu H; Gao J; Tokheim C; Zhou DC; Johnson AM; Zeng J; Ip CKM; Ju Z; Wester M; Yu S; Li Y; Vellano CP; Schultz N; Karchin R; Ding L; Lu Y; Cheung LWT; Chen K; Shaw KR; Meric-Bernstam F; Scott KL; Yi S; Sahni N; Liang H; Mills GB
Cancer Cell; 2018 Mar; 33(3):450-462.e10. PubMed ID: 29533785
[TBL] [Abstract][Full Text] [Related]
2. Radotinib and its clinical potential in chronic-phase chronic myeloid leukemia patients: an update.
Eskazan AE; Keskin D
Ther Adv Hematol; 2017 Sep; 8(9):237-243. PubMed ID: 29051802
[TBL] [Abstract][Full Text] [Related]
3. Analysis of mutation profiles in extranodal NK/T-cell lymphoma: clinical and prognostic correlations.
Chang YC; Tsai HJ; Huang TY; Su NW; Su YW; Chang YF; Chen CG; Lin J; Chang MC; Chen SJ; Chen HC; Lim KH; Chang KC; Kuo SH
Ann Hematol; 2024 Apr; ():. PubMed ID: 38671297
[TBL] [Abstract][Full Text] [Related]
4. Structural Analysis of Janus Tyrosine Kinase Variants in Hematological Malignancies: Implications for Drug Development and Opportunities for Novel Therapeutic Strategies.
Rodriguez Moncivais OJ; Chavez SA; Estrada Jimenez VH; Sun S; Li L; Kirken RA; Rodriguez G
Int J Mol Sci; 2023 Sep; 24(19):. PubMed ID: 37834019
[TBL] [Abstract][Full Text] [Related]
5. JAK3 Y841 Autophosphorylation Is Critical for STAT5B Activation, Kinase Domain Stability and Dimer Formation.
Rodriguez G; Martinez GS; Negrete OD; Sun S; Guo W; Xie Y; Li L; Xiao C; Ross JA; Kirken RA
Int J Mol Sci; 2023 Jul; 24(15):. PubMed ID: 37569303
[TBL] [Abstract][Full Text] [Related]
6. JAK1 Pseudokinase V666G Mutant Dominantly Impairs JAK3 Phosphorylation and IL-2 Signaling.
Grant AH; Rodriguez AC; Rodriguez Moncivais OJ; Sun S; Li L; Mohl JE; Leung MY; Kirken RA; Rodriguez G
Int J Mol Sci; 2023 Apr; 24(7):. PubMed ID: 37047778
[TBL] [Abstract][Full Text] [Related]
7. Identification of U937
Si H; Wang J; He R; Yu X; Li S; Huang J; Li J; Tang X; Song X; Tu Z; Zhang Z; Ding K
Front Oncol; 2021; 11():807200. PubMed ID: 35111683
[TBL] [Abstract][Full Text] [Related]
8. Targeted Deep Sequencing of Mycosis Fungoides Reveals Intracellular Signaling Pathways Associated with Aggressiveness and Large Cell Transformation.
Wobser M; Roth S; Appenzeller S; Houben R; Schrama D; Goebeler M; Geissinger E; Rosenwald A; Maurus K
Cancers (Basel); 2021 Nov; 13(21):. PubMed ID: 34771672
[TBL] [Abstract][Full Text] [Related]
9. Untwining Anti-Tumor and Immunosuppressive Effects of JAK Inhibitors-A Strategy for Hematological Malignancies?
Klein K; Stoiber D; Sexl V; Witalisz-Siepracka A
Cancers (Basel); 2021 May; 13(11):. PubMed ID: 34073410
[TBL] [Abstract][Full Text] [Related]
10. Deregulation of the Interleukin-7 Signaling Pathway in Lymphoid Malignancies.
Lodewijckx I; Cools J
Pharmaceuticals (Basel); 2021 May; 14(5):. PubMed ID: 34066732
[TBL] [Abstract][Full Text] [Related]
11. Failure of tofacitinib to achieve an objective response in a
Wong J; Wall M; Corboy GP; Taubenheim N; Gregory GP; Opat S; Shortt J
Cold Spring Harb Mol Case Stud; 2020 Aug; 6(4):. PubMed ID: 32843425
[TBL] [Abstract][Full Text] [Related]
12. JAK/STAT-Activating Genomic Alterations Are a Hallmark of T-PLL.
Wahnschaffe L; Braun T; Timonen S; Giri AK; Schrader A; Wagle P; Almusa H; Johansson P; Bellanger D; López C; Haferlach C; Stern MH; Dürig J; Siebert R; Mustjoki S; Aittokallio T; Herling M
Cancers (Basel); 2019 Nov; 11(12):. PubMed ID: 31766351
[TBL] [Abstract][Full Text] [Related]
13. Are peptides a solution for the treatment of hyperactivated JAK3 pathways?
Dullius A; Rocha CM; Laufer S; de Souza CFV; Goettert MI
Inflammopharmacology; 2019 Jun; 27(3):433-452. PubMed ID: 30929155
[TBL] [Abstract][Full Text] [Related]
14. Oncogenic activation of the STAT3 pathway drives PD-L1 expression in natural killer/T-cell lymphoma.
Song TL; Nairismägi ML; Laurensia Y; Lim JQ; Tan J; Li ZM; Pang WL; Kizhakeyil A; Wijaya GC; Huang DC; Nagarajan S; Chia BK; Cheah D; Liu YH; Zhang F; Rao HL; Tang T; Wong EK; Bei JX; Iqbal J; Grigoropoulos NF; Ng SB; Chng WJ; Teh BT; Tan SY; Verma NK; Fan H; Lim ST; Ong CK
Blood; 2018 Sep; 132(11):1146-1158. PubMed ID: 30054295
[TBL] [Abstract][Full Text] [Related]
15. Transforming Mutations of Jak3 (A573V and M511I) Show Differential Sensitivity to Selective Jak3 Inhibitors.
Martinez GS; Ross JA; Kirken RA
Clin Cancer Drugs; 2016; 3(2):131-137. PubMed ID: 29046866
[TBL] [Abstract][Full Text] [Related]
16. Identification of mutant alleles of JAK3 in pediatric patients with acute lymphoblastic leukemia.
Yin C; Sandoval C; Baeg GH
Leuk Lymphoma; 2015 May; 56(5):1502-6. PubMed ID: 25146434
[TBL] [Abstract][Full Text] [Related]
17. Mutant JAK3 phosphoproteomic profiling predicts synergism between JAK3 inhibitors and MEK/BCL2 inhibitors for the treatment of T-cell acute lymphoblastic leukemia.
Degryse S; de Bock CE; Demeyer S; Govaerts I; Bornschein S; Verbeke D; Jacobs K; Binos S; Skerrett-Byrne DA; Murray HC; Verrills NM; Van Vlierberghe P; Cools J; Dun MD
Leukemia; 2018 Mar; 32(3):788-800. PubMed ID: 28852199
[TBL] [Abstract][Full Text] [Related]
18. In vivo impact of JAK3 A573V mutation revealed using zebrafish.
Basheer F; Bulleeraz V; Ngo VQT; Liongue C; Ward AC
Cell Mol Life Sci; 2022 May; 79(6):322. PubMed ID: 35622134
[TBL] [Abstract][Full Text] [Related]
19. Selective inhibitors of the Janus kinase Jak3--Are they effective?
Thoma G; Drückes P; Zerwes HG
Bioorg Med Chem Lett; 2014 Oct; 24(19):4617-4621. PubMed ID: 25217444
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
